Abbott Laboratories (NYSE:ABT)

Abbott Laboratories ABT

Healthcare - Medical - Devices - NYSE - US

Watchlist

$ 115.9

0.756 %

$ 201 B

Market Cap

35.23

P/E

1. INTRINSIC VALUE

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories.[ Read More ]

The intrinsic value of one ABT stock under the base case scenario is HIDDEN Compared to the current market price of 116 USD, Abbott Laboratories is HIDDEN

ABT Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart ABT

FINANCIALS

Annual
Quarterly

40.1 B REVENUE

Growth Rates

1Year -8.12%

3Years 5.04%

5Years 5.58%

7Years 9.79%

10Years 6.26%

6.48 B OPERATING INCOME

Growth Rates

1Year -22.53%

3Years 6.54%

5Years 12.16%

7Years 10.67%

10Years 9.44%

5.72 B NET INCOME

Growth Rates

1Year -17.45%

3Years 8.38%

5Years 19.30%

7Years 22.60%

10Years 8.31%

7.26 B OPERATING CASH FLOW

Growth Rates

1Year -24.21%

3Years -2.78%

5Years 2.88%

7Years 12.40%

10Years 8.13%

-3.13 B INVESTING CASH FLOW

Growth Rates

1Year -80.06%

3Years -12.25%

5Years -18.23%

7Years -43.67%

10Years 2.24%

-7.09 B FINANCING CASH FLOW

Growth Rates

1Year 7.14%

3Years -36.65%

5Years 7.36%

7Years -7.29%

10Years -0.57%

10.6 B REVENUE

Growth Rates

1Year -8.12%

3Years 5.04%

5Years 5.58%

7Years 9.79%

10Years 6.26%

1.86 B OPERATING INCOME

Growth Rates

1Year -22.53%

3Years 6.54%

5Years 12.16%

7Years 10.67%

10Years 9.44%

1.65 B NET INCOME

Growth Rates

1Year -17.45%

3Years 8.38%

5Years 19.30%

7Years 22.60%

10Years 8.31%

2.7 B OPERATING CASH FLOW

Growth Rates

1Year -24.21%

3Years -2.78%

5Years 2.88%

7Years 12.40%

10Years 8.13%

-594 M INVESTING CASH FLOW

Growth Rates

1Year -80.06%

3Years -12.25%

5Years -18.23%

7Years -43.67%

10Years 2.24%

-1.58 B FINANCING CASH FLOW

Growth Rates

1Year 7.14%

3Years -36.65%

5Years 7.36%

7Years -7.29%

10Years -0.57%

Balance Sheet Decomposition Abbott Laboratories

73.2 B ASSETS
34.4 B LIABILITIES

Current Assets	22.7 B
Cash & Short-Term Investments	7.28 B
Receivables	6.56 B
Other Current Assets	8.83 B
Non-Current Assets	50.5 B
Long-Term Investments	799 M
PP&E	11.3 B
Other Non-Current Assets	38.5 B

Current Liabilities	13.8 B
Accounts Payable	4.3 B
Short-Term Debt	1.08 B
Other Current Liabilities	8.47 B
Non-Current Liabilities	20.5 B
Long-Term Debt	14.5 B
Other Non-Current Liabilities	6 B

EFFICIENCY

Earnings Waterfall Abbott Laboratories

Revenue	40.1 B
Cost Of Revenue	18 B
Gross Profit	22.1 B
Operating Expenses	15.7 B
Operating Income	6.48 B
Other Expenses	755 M
Net Income	5.72 B

RATIOS

55.18% GROSS MARGIN

Averages

1Year 55.18%

3Years 56.10%

5Years 56.70%

7Years 56.70%

10Years 56.52%

16.15% OPERATING MARGIN

Averages

1Year 16.15%

3Years 18.29%

5Years 16.91%

7Years 14.68%

10Years 14.49%

14.27% NET MARGIN

Averages

1Year 14.27%

3Years 15.52%

5Years 14.22%

7Years 11.51%

10Years 12.03%

14.83% ROE

Averages

1Year 14.83%

3Years 17.82%

5Years 15.81%

7Years 12.62%

10Years 12.66%

7.82% ROA

Averages

1Year 7.82%

3Years 8.84%

5Years 7.63%

7Years 6.04%

10Years 6.12%

10.44% ROIC

Averages

1Year 10.44%

3Years 12.32%

5Years 10.93%

7Years 8.72%

10Years 8.05%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Abbott Laboratories

Net Income	5.72 B
Depreciation & Amortization	3.24 B
Capital Expenditures	-2.2 B
Stock-Based Compensation	644 M
Change in Working Capital	-2.48 B
Others	-1 B
Free Cash Flow	5.06 B

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Abbott Laboratories

Wall Street analysts predict an average 1-year price target for ABT of $135 , with forecasts ranging from a low of $50 to a high of $345 .

ABT Lowest Price Target Wall Street Target

50 USD -56.86%

ABT Average Price Target Wall Street Target

135 USD 16.52%

ABT Highest Price Target Wall Street Target

345 USD 197.67%

4. DIVIDEND ANALYSIS

0.49% DIVIDEND YIELD

0.55 USD DIVIDEND PER SHARE

5. COMPETITION

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

596 USD

ABBV

Undervalued 261.45%

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

268 USD

LLY

Overvalued 64.14%

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.

465 USD

BMY

Undervalued 726.43%

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

163 USD

JNJ

Undervalued 6.01%

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

101 USD

MDT

Undervalued 15.64%

6. Ownership

Insider Ownership Abbott Laboratories

Summary
Transactions

Sold

0-3 MONTHS

34.9 M USD 3

3-6 MONTHS

0 USD 0

6-9 MONTHS

5.51 M USD 8

9-12 MONTHS

3.59 M USD 1

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
3 weeks ago Oct 21, 2024	Sell 148 K USD	ALLEN HUBERT L EXECUTIVE VICE PRESIDENT	- 1249	118.81 USD
3 weeks ago Oct 21, 2024	Sell 697 K USD	ALLEN HUBERT L EXECUTIVE VICE PRESIDENT	- 5901	118.15 USD
3 weeks ago Oct 21, 2024	Sell 17.6 M USD	ALLEN HUBERT L EXECUTIVE VICE PRESIDENT	- 150271	116.98 USD
2 months ago Sep 12, 2024	Sell 9.32 M USD	Ford Robert B CHAIRMAN AND CEO	- 80299	116.04 USD
2 months ago Sep 12, 2024	Sell 7.18 M USD	Ford Robert B CHAIRMAN AND CEO	- 61380	116.9 USD
2 months ago Sep 04, 2024	Sell 3.1 K USD	MCCOY JOHN A. JR. VICE PRESIDENT	- 27	114.83 USD
6 months ago May 10, 2024	Sell 1.06 M USD	Funck, Jr. Robert E. EXECUTIVE VICE PRESIDENT	- 10097	104.5676 USD
6 months ago May 07, 2024	Sell 2.43 M USD	Earnhardt Lisa D EXECUTIVE VICE PRESIDENT	- 22852	106.2541 USD
8 months ago Mar 01, 2024	Sell 114 K USD	Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT	- 963	118.5 USD
8 months ago Mar 01, 2024	Sell 94.9 K USD	Morrone Louis H. EXECUTIVE VICE PRESIDENT	- 801	118.5 USD
8 months ago Mar 01, 2024	Sell 80.1 K USD	Moreland Mary K EXECUTIVE VICE PRESIDENT	- 676	118.5 USD
8 months ago Mar 01, 2024	Sell 55.9 K USD	MCCOY JOHN A. JR. VICE PRESIDENT	- 472	118.5 USD
8 months ago Mar 01, 2024	Sell 82.2 K USD	Earnhardt Lisa D EXECUTIVE VICE PRESIDENT	- 694	118.5 USD
8 months ago Mar 01, 2024	Sell 101 K USD	ALLEN HUBERT L EXECUTIVE VICE PRESIDENT	- 853	118.5 USD
8 months ago Feb 23, 2024	Sell 1.5 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 12500	120 USD
9 months ago Jan 29, 2024	Sell 1.97 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 17500	112.5 USD
11 months ago Dec 14, 2023	Sell 1.62 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 15000	108 USD
1 year ago Oct 26, 2023	Sell 2.52 M USD	STARKS DANIEL J Director	- 26907	93.8141 USD
1 year ago Oct 26, 2023	Sell 2.18 M USD	STARKS DANIEL J Director	- 23093	94.326 USD
1 year ago Aug 08, 2023	Sell 498 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 4741	105 USD
1 year ago Aug 08, 2023	Sell 25.7 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 244	105.43 USD
1 year ago Aug 08, 2023	Sell 1.61 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 15	107.42 USD
1 year ago Aug 08, 2023	Sell 537 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 5112	105 USD
1 year ago Aug 08, 2023	Sell 28.7 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 272	105.43 USD
1 year ago Aug 08, 2023	Sell 1.72 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 16	107.42 USD
1 year ago Jul 27, 2023	Sell 2.37 M USD	STARKS DANIEL J Director	- 20934	113.4283 USD
1 year ago Jul 27, 2023	Sell 3.31 M USD	STARKS DANIEL J Director	- 29066	114.0054 USD
1 year ago Jun 16, 2023	Sell 848 K USD	Boudreau Philip P VICE PRESIDENT	- 8000	106 USD
1 year ago May 02, 2023	Sell 909 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 8226	110.5607 USD
1 year ago May 02, 2023	Sell 5.17 M USD	STARKS DANIEL J Director	- 46548	110.97 USD
1 year ago May 02, 2023	Sell 386 K USD	STARKS DANIEL J Director	- 3452	111.75 USD
1 year ago Mar 01, 2023	Sell 104 K USD	WOODGRIFT RANDEL WILLIAM SENIOR VICE PRESIDENT	- 1032	100.7 USD
1 year ago Mar 01, 2023	Sell 121 K USD	Watkin Jared SENIOR VICE PRESIDENT	- 1198	100.7 USD
1 year ago Mar 01, 2023	Sell 68.4 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 679	100.7 USD
1 year ago Mar 01, 2023	Sell 52.9 K USD	Tyler Julie L. SENIOR VICE PRESIDENT	- 525	100.7 USD
1 year ago Mar 01, 2023	Sell 109 K USD	Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT	- 1085	100.7 USD
2 years ago Mar 01, 2022	Sell 110 K USD	Morrone Louis H. SENIOR VICE PRESIDENT	- 1092	100.7 USD
1 year ago Mar 01, 2023	Sell 72.3 K USD	Moreland Mary K EXECUTIVE VICE PRESIDENT	- 717	100.77 USD
1 year ago Mar 01, 2023	Sell 135 K USD	MANNING JOSEPH J EXECUTIVE VICE PRESIDENT	- 1339	100.7 USD
1 year ago Mar 01, 2023	Sell 95 K USD	Ginascol John F EXECUTIVE VICE PRESIDENT	- 943	100.7 USD
1 year ago Mar 01, 2023	Sell 127 K USD	Funck, Jr. Robert E. EXECUTIVE VICE PRESIDENT	- 1264	100.7 USD
1 year ago Mar 01, 2023	Sell 95 K USD	Earnhardt Lisa D EXECUTIVE VICE PRESIDENT	- 943	100.7 USD
1 year ago Mar 01, 2023	Sell 122 K USD	DALE MICHAEL D SENIOR VICE PRESIDENT	- 1209	100.7 USD
1 year ago Mar 01, 2023	Sell 108 K USD	ALLEN HUBERT L EXECUTIVE VICE PRESIDENT	- 1069	100.7 USD
1 year ago Mar 01, 2023	Sell 133 K USD	Ahlberg Gregory A SENIOR VICE PRESIDENT	- 1317	100.7 USD
1 year ago Feb 22, 2023	Sell 26.8 K USD	Tyler Julie L. SENIOR VICE PRESIDENT	- 260	103.24 USD
1 year ago Dec 29, 2022	Sell 457 K USD	Karam Sammy director: SENIOR VICE PRESIDENT	- 4200	108.75 USD
1 year ago Dec 13, 2022	Sell 1.24 M USD	Ginascol John F director: EXECUTIVE VICE PRESIDENT	- 11000	112.32 USD
2 years ago Oct 27, 2022	Sell 3.96 M USD	STARKS DANIEL J Director	- 40687	97.3036 USD
2 years ago Oct 27, 2022	Sell 914 K USD	STARKS DANIEL J Director	- 9313	98.136 USD
2 years ago Aug 25, 2022	Sell 10.8 M USD	Ford Robert B director: CHAIRMAN AND CEO	- 102425	105.1028 USD
2 years ago Aug 25, 2022	Sell 2.42 M USD	MANNING JOSEPH J EXECUTIVE VICE PRESIDENT	- 23008	104.9941 USD
2 years ago Aug 25, 2022	Sell 409 K USD	MANNING JOSEPH J director: EXECUTIVE VICE PRESIDENT	- 3890	105.24 USD
2 years ago Jul 26, 2022	Sell 3.02 M USD	STARKS DANIEL J director:	- 27749	108.767 USD
2 years ago Jul 26, 2022	Sell 2.44 M USD	STARKS DANIEL J Director	- 22251	109.6049 USD
2 years ago Jul 26, 2022	Sell 268 K USD	Mateus Fernando director: SENIOR VICE PRESIDENT	- 2457	109.0529 USD
2 years ago Jul 25, 2022	Sell 27.6 K USD	Tyler Julie L. director: SENIOR VICE PRESIDENT	- 253	109.09 USD
2 years ago May 04, 2022	Sell 2.71 M USD	WOODGRIFT RANDEL WILLIAM director: SENIOR VICE PRESIDENT	- 24000	113.0043 USD
2 years ago May 03, 2022	Sell 1.89 M USD	STARKS DANIEL J Director	- 16822	112.5148 USD
2 years ago May 03, 2022	Sell 3.07 M USD	STARKS DANIEL J Director	- 27055	113.2934 USD
2 years ago May 03, 2022	Sell 703 K USD	STARKS DANIEL J director:	- 6123	114.8409 USD
2 years ago Mar 08, 2022	Sell 468 K USD	DALE MICHAEL D director: SENIOR VICE PRESIDENT	- 4000	117.0003 USD
2 years ago Mar 01, 2022	Sell 114 K USD	WOODGRIFT RANDEL WILLIAM SENIOR VICE PRESIDENT	- 964	118.101 USD
2 years ago Mar 01, 2022	Sell 123 K USD	Watkin Jared SENIOR VICE PRESIDENT	- 1038	118.101 USD
2 years ago Mar 01, 2022	Sell 53.9 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 456	118.128 USD
2 years ago Mar 01, 2022	Sell 183 K USD	Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT	- 1550	118.171 USD
2 years ago Mar 01, 2022	Sell 77.5 K USD	Morrone Louis H. SENIOR VICE PRESIDENT	- 656	118.1603 USD
2 years ago Mar 01, 2022	Sell 92 K USD	MANNING JOSEPH J EXECUTIVE VICE PRESIDENT	- 779	118.1602 USD
3 years ago Mar 01, 2021	Sell 43.1 K USD	Ginascol John F EXECUTIVE VICE PRESIDENT	- 365	118.1602 USD
2 years ago Mar 01, 2022	Sell 111 K USD	Earnhardt Lisa D EXECUTIVE VICE PRESIDENT	- 943	118.1503 USD
2 years ago Mar 01, 2022	Sell 124 K USD	DALE MICHAEL D SENIOR VICE PRESIDENT	- 1053	118.1503 USD
2 years ago Mar 01, 2022	Sell 83.4 K USD	Calamari Christopher J. SENIOR VICE PRESIDENT	- 706	118.1503 USD
2 years ago Mar 01, 2022	Sell 171 K USD	ALLEN HUBERT L EXECUTIVE VICE PRESIDENT	- 1450	118.171 USD
2 years ago Mar 01, 2022	Sell 130 K USD	Ahlberg Gregory A SENIOR VICE PRESIDENT	- 1099	118.1503 USD
2 years ago Feb 24, 2022	Sell 188 K USD	McKinstry Nancy Director	- 1614	116.425 USD
2 years ago Feb 22, 2022	Sell 55.1 K USD	Tyler Julie L. SENIOR VICE PRESIDENT	- 462	119.2944 USD
3 years ago Feb 22, 2021	Sell 47.7 K USD	Moreland Mary K EXECUTIVE VICE PRESIDENT	- 400	119.3067 USD
2 years ago Dec 23, 2021	Sell 428 K USD	Wainer Andrea F director: EXECUTIVE VICE PRESIDENT	- 3000	142.5 USD
2 years ago Dec 23, 2021	Sell 1.82 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 13000	140 USD
2 years ago Dec 23, 2021	Sell 658 K USD	Karam Sammy SENIOR VICE PRESIDENT	- 4700	140.0049 USD
2 years ago Dec 23, 2021	Sell 8.19 M USD	Salvadori Daniel Gesua Sive director: EXECUTIVE VICE PRESIDENT	- 58501	140 USD
2 years ago Dec 17, 2021	Sell 1.37 M USD	Morrone Louis H. SENIOR VICE PRESIDENT	- 9988	137.54 USD
2 years ago Dec 17, 2021	Sell 1.03 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 7500	137.54 USD
2 years ago Dec 13, 2021	Sell 1.96 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 14500	135 USD
2 years ago Dec 13, 2021	Sell 7.42 M USD	Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT	- 55000	135 USD
2 years ago Dec 13, 2021	Sell 20.2 M USD	CAPEK JOHN M director: EXECUTIVE VICE PRESIDENT	- 149600	135.0515 USD
2 years ago Dec 06, 2021	Sell 596 K USD	Wainer Andrea F director: EXECUTIVE VICE PRESIDENT	- 4500	132.5 USD
2 years ago Dec 06, 2021	Sell 1.31 M USD	Morrone Louis H. SENIOR VICE PRESIDENT	- 9989	131.0125 USD
2 years ago Dec 07, 2021	Sell 1.34 M USD	Morrone Louis H. SENIOR VICE PRESIDENT	- 9988	134 USD
3 years ago Nov 15, 2021	Sell 1.3 M USD	LANE ANDREW H EXECUTIVE VICE PRESIDENT	- 10000	130.009 USD
3 years ago Nov 15, 2021	Sell 1.63 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 12500	130.0089 USD
3 years ago Nov 15, 2021	Sell 2.8 M USD	Ahlberg Gregory A SENIOR VICE PRESIDENT	- 21568	130 USD
3 years ago Nov 15, 2021	Sell 508 K USD	Ahlberg Gregory A SENIOR VICE PRESIDENT	- 3905	130 USD
3 years ago Oct 25, 2021	Sell 1.01 M USD	Boudreau Philip P VICE PRESIDENT	- 8000	126.49 USD
3 years ago Sep 08, 2021	Sell 2.97 M USD	PEDERSON MICHAEL J SENIOR VICE PRESIDENT	- 23008	129.0496 USD
3 years ago Sep 03, 2021	Sell 129 K USD	WOODGRIFT RANDEL WILLIAM director: SENIOR VICE PRESIDENT	- 1000	129 USD
3 years ago Sep 03, 2021	Sell 690 K USD	WOODGRIFT RANDEL WILLIAM director: SENIOR VICE PRESIDENT	- 5350	129 USD
3 years ago Sep 02, 2021	Sell 1.21 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 9500	127.5 USD
3 years ago Aug 27, 2021	Sell 17.1 M USD	LANE ANDREW H director: EXECUTIVE VICE PRESIDENT	- 135925	125.475 USD
3 years ago Aug 17, 2021	Sell 1 M USD	Karam Sammy SENIOR VICE PRESIDENT	- 8000	125 USD
3 years ago Aug 17, 2021	Sell 1.81 M USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 14500	125 USD
3 years ago Aug 03, 2021	Sell 980 K USD	Karam Sammy SENIOR VICE PRESIDENT	- 8000	122.5 USD
3 years ago Jul 28, 2021	Sell 2.12 M USD	DALE MICHAEL D SENIOR VICE PRESIDENT	- 17600	120.3342 USD
3 years ago Apr 30, 2021	Sell 1.14 M USD	Watkin Jared SENIOR VICE PRESIDENT	- 9533	120.016 USD
3 years ago Apr 30, 2021	Sell 10.2 M USD	Watkin Jared SENIOR VICE PRESIDENT	- 85043	119.8879 USD
3 years ago Apr 27, 2021	Sell 1.05 M USD	Karam Sammy SENIOR VICE PRESIDENT	- 8600	122 USD
3 years ago Apr 27, 2021	Sell 1.15 M USD	BIRD ROGER SENIOR VICE PRESIDENT	- 9439	122 USD
3 years ago Mar 03, 2021	Sell 755 K USD	Wainer Andrea F EXECUTIVE VICE PRESIDENT	- 6200	121.79 USD
3 years ago Mar 01, 2021	Sell 125 K USD	WOODGRIFT RANDEL WILLIAM SENIOR VICE PRESIDENT	- 1034	120.61 USD
3 years ago Mar 01, 2021	Sell 168 K USD	Watkin Jared SENIOR VICE PRESIDENT	- 1391	120.61 USD

7. News

3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years These are income stocks you can buy and hold forever. fool.com - 3 days ago

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever You'll also like these stocks for their track record of earnings growth. fool.com - 1 week ago

PAHC or ABT: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 week ago

Abbott Laboratories Employees Credit Union ("ALECU") Data Breach - Levi & Korsinsky, LLP Launches Investigates NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers.This data breach has led to concerns over the security of sensitive private information entrusted to ALECU. WHAT'S THIS ABOUT? accesswire.com - 1 week ago

Abbott India posts Q2 profit rise on strong demand, price hikes Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. reuters.com - 1 week ago

Levi & Korsinsky, LLP Investigates Abbott Laboratories Employees Credit Union ("ALECU") Data Breach NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the security of sensitive private information entrusted to ALECU. accesswire.com - 1 week ago

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. zacks.com - 1 week ago

Levi & Korsinsky, LLP Investigates Abbott Laboratories Employees Credit Union ("ALECU") Data Breach NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Abbott Laboratories Employees Credit Union ("ALECU")recently disclosed a data breach that compromised the sensitive personal data of thousands of customers.This data breach has led to concerns over the security of sensitive private information entrusted to ALECU. WHAT'S THIS ABOUT? accesswire.com - 1 week ago

The lawsuits against Abbott 'really steam me', says Jim Cramer 'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs. youtube.com - 2 weeks ago

Jim Cramer takes a closer looks at the litigation facing Abbott and what it means for the company 'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs. youtube.com - 2 weeks ago

Abbott Laboratories Employees Credit Union ("ALECU") Data Breach - Levi & Korsinsky, LLP Launches Investigation NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Abbott Laboratories Employees Credit Union ("ALECU") recently disclosed a data breach that compromised the sensitive personal data of thousands of customers. This data breach has led to concerns over the security of sensitive private information entrusted to ALECU. accesswire.com - 2 weeks ago

Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win Shares of Abbott Laboratories (ABT) are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's debilitating intestinal disease. investopedia.com - 2 weeks ago

8. Profile Summary

Abbott Laboratories ABT

COUNTRY US

INDUSTRY Medical - Devices

MARKET CAP $ 201 B

Dividend Yield 0.49%

Description Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Contact 100 Abbott Park Road, North Chicago, IL, 60064-6400 https://www.abbott.com

IPO Date March 17, 1980

Employees 114000

Officers Mr. Christopher J. Scoggins Senior Vice President of Commercial Operations, Marketing & Diabetes Care Ms. Melissa Brotz Vice President of Public Affairs & Corporate Marketing Mr. Hubert L. Allen J.D. Executive Vice President, General Counsel & Secretary Mr. Michael Comilla Vice President of Investor Relations. Erica L. Battaglia Vice President and Chief Ethics & Compliance Officer Mr. Robert B. Ford Chairman of the Board, President & Chief Executive Officer Ms. Sabina Ewing Senior Vice President of Business & Technology Services and Chief Information Officer Mr. Philip P. Boudreau Chief Financial Officer & Executive Vice President of Finance Mr. Daniel Gesua Sive Salvadori Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products Ms. Lisa D. Earnhardt Executive Vice President & Group President of Medical Devices

Price Chart ABT

Abbott Laboratories ABT

Premium Plan

Unlimited Plan